With these protocol approvals, clinicians can use AutoloGel(TM) to treat Medicare beneficiaries with chronic wounds and receive reimbursement for the product under the Coverage with Evidence Development (CED) program. CMXI expects to begin rolling out the protocols to wound care clinics during March, and anticipates the first patients will be treated under the protocols soon. CMXI closed at $0.50 on 3/1/13. Ranked a “BUY” as it appears Osiris’ Grafix also targets diabetic ulcers, it appears to have direct overlap with CMXI ‘s AutoloGel . However, under the approved protocols, CMXI … expects to treat more than 1,200 patients with AutoloGel in outpatient wound care centers affiliated with Intellicure and the US Wound Registry while OSIR has to develop a sales and marketing group to advance.